Key Takeaways
- • Bain Capital is acquiring Vitabiotics, a UK-based multivitamin company, for £900 million, with the deal expected to be finalized imminently as of late May 2026.
- • Tej Lalvani, founder's son and current CEO of Vitabiotics, has led the company since 2015 and is known as a Dragons' Den investor; the business was originally established by his father Kartar Lalvani over 50 years ago.
- • Under Tej Lalvani's leadership, Vitabiotics has grown revenues from £101 million to £195.6 million over 11 years, with key brands including Wellwoman, Perfectil, and Pregnacare.
- • The transaction values Vitabiotics at approximately £900 million ($1.2 billion USD), positioning it as a significant acquisition within the consumer health and wellness sector.
- • Multiple private equity firms including Blackstone were reported as contenders in earlier bidding rounds, though Bain Capital emerged as the sole lead bidder for the final transaction.
Summary
Tej Lalvani, 51, who assumed the role of chief executive in 2015, has spearheaded the company's growth trajectory and is widely recognized as an investor on BBC Two's Dragons' Den, where he appeared from 2017 to 2021. The company itself was founded by his father, Kartar Lalvani, more than five decades ago. During Tej's tenure, Vitabiotics has expanded significantly, growing revenues from £101 million to £195.6 million. The company's portfolio includes established consumer wellness brands such as Wellwoman, Perfectil, and Pregnacare, and has attracted backing from high-profile celebrities including Strictly Come Dancing host Tess Daly, supermodel David Gandy, and television presenter Davina McCall.
The acquisition process drew interest from multiple major private equity players. Bloomberg reported that both Bain Capital and Blackstone were among suitors in the bidding rounds, though Bain Capital ultimately emerged as the lead bidder in final negotiations. According to sources close to the transaction, while discussions have advanced to a critical stage, negotiations remain delicate, and sources have cautioned that completion cannot be assumed with absolute certainty. The valuation of approximately £900 million reflects strong interest in the consumer health sector and underscores the profitability and brand strength of Vitabiotics' established market position in vitamins and nutritional supplements.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.